FebriDX

FebriDx®, developed by Lumos Diagnostic, is the first of its kind, rapid point-of-care assay that uses a fingerstick blood sample to aid in the differentiation of bacterial from viral infection. FebriDx® has a 99% Negative Predictive Value (NPV), which means it is extremely accurate in ruling out a bacterial infection when evaluating patients exhibiting symptoms of acute respiratory infection. 

By combining the acute phase inflammatory protein, CRP (C-Reactive Protein), with a specific viral marker, MxA (Myxovirus resistance protein A), FebriDx® achieves the sensitivity and specificity to aid in the differentiation of bacterial from non-bacterial acute respiratory infection.   FebriDx® has a achieved 99% NPV to rule out a bacterial infection.

For more information on the science, please see our Studies and Literature page. 

Delivers results in 10 minutes at the point-of-care. This means the assays results are available to the healthcare provider prior to prescribing antibiotics or evaluating additional tests. 

• Improved patient outcomes because doctors confidently rule out bacterial infection and eliminate the side effects of unneeded antibiotics
• Improved antimicrobial stewardship because doctors can confidently rule out bacterial infection at the point of care and eliminate the prescription of unneeded antibiotics
• Increased efficiency in hospital operations by reducing the amount of time needed to evaluate patients

The assay requires no additional lab equipment. This makes the assay incredibly efficient to administer and differentiates it form all other methods available to make the same diagnosis today. 

• Results are available 24/7 and not dependent on lab operations
• Low cost of adoption as the hospital does not need to order or maintain any additional lab equipment to improve patient outcomes

• Improved decision making at the point of care. Healthcare providers can rule out bacterial infection prior to prescribing medication or evaluating treatment options
• Improved patient outcomes and antimicrobial stewardship. Patients receive antibiotics when they need them and not when they don’t.
• Increased margins and more efficient operations for healthcare providers. FebriDx has approved billing codes for assay administration. It also reduces the hospital resources required to deliver a confident patient diagnosis. 
• Increased savings for both patients and insurance companies. The assay allows healthcare providers to make more confident diagnoses in a more efficient manner. It also improves antimicrobial stewardship, thereby reducing future healthcare costs.  For more information on the economic impact of adopting FebriDx please see the economic evaluation study on our Studies and Literature page.

Healthiture is an approved distributor of FebriDx. We are confident that we can deliver the assay at a more competitive price than any other distributor in the market.

Additional Information:

• Manufactured in the USA
• Categorized as a Moderate Complexity Laboratory Test NOT CLIA-Waived
• Established PLA Code 
• Target Audience: Primary Care, Urgent Care and Community Health Center
• Shelf Life: 

             FebriDx® Test Kit - 18 months from the date of manufacture

             FebriDx® External Controls - 10 months from the date of manufacture